Vaccines
28 September 2021
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate28 September 2021
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate27 September 2021
CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine23 September 2021
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster20 September 2021
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer20 September 2021
Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years18 September 2021
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations15 September 2021
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate15 September 2021
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-1915 September 2021
Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta9 September 2021
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, including the Delta Variant9 September 2021
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza4 September 2021
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster2 September 2021
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster2 September 2021
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)2 September 2021
Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate1 September 2021
Entos Pharmaceuticals’ COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South AfricaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports